Previous 10 | Next 10 |
PLEASANTON, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced that the Company has commenced an underwritten public offering of 3,500,000 shares of the Company’s Class A common stock to be issued by the Company p...
A special purpose acquisition company (SPAC) is a publicly traded shell company that raises capital with the intent of acquiring a private business. SPACs have become an intriguing alternative for companies that want to go public because they allow that to happen much faster than with an init...
PLEASANTON, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference. 10x Genomics’ management is scheduled to participate in a fireside chat on Wednesday, S...
Quick Take 10x Genomics ( TXG ) went public in September 2019, selling 10 million shares of stock at $39.00, raising $390 million in gross proceeds, excluding underwriter shares. The firm provides a range of equipment and software for genetic research purposes. TXG has strong prospects...
10x Genomics, Inc. (TXG) Q2 2020 Results Conference Call August 11, 2020 4:30 PM ET Company Participants Eric Jaschke - Director of Investor Relations and Strategic Finance Serge Saxonov - Co-Founder & Chief Executive Officer Justin McAnear - Chief Financial Officer Brad...
10x Genomics (NASDAQ: TXG ) : Q2 GAAP EPS of -$0.41 beats by $0.13 . More news on: 10x Genomics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
PLEASANTON, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the second quarter ended June 30, 2020. Recent Highlights Revenue was $42.9 million for the second quarter, representing a 23% decrease over the correspon...
PLEASANTON, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming UBS Genomics 2.0 and Medtech Innovations Virtual Summit. 10x Genomics’ management is scheduled to participate in a fireside chat on We...
The U.S. Court of Appeals for the Federal Circuit has affirmed a lower court ruling that 10x Genomics ( TXG -0.7% ) willfully infringed on U.S. Patent No. 8,889,083 that Bio-Rad Laboratories ( BIO -1.4% ) exclusively licensed from the University of Chicago. More news on: 10x Genomics...
A Zebrafish embryo at an early stage of development ( Jeffrey Farrell, Schier Lab /Harvard University) Investment Thesis 10x Genomics ( TXG ) is leading the cell revolution hailed by the prestigious Science Magazine as the “breakthrough of the year“ in 2018. The market is i...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:00:09 ET Kyle Mikson from Canaccord Genuity issued a price target of $32.00 for TXG on 2024-07-23 05:09:00. The adjusted price target was set to $32.00. At the time of the announcement, TXG was trading at $18.11. The overall price target consensus is at $24...
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report fi...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...